Co-Localization of the Oncogenic Transcription Factor MYCN and the DNA Methyl Binding Protein MeCP2 at Genomic Sites in Neuroblastoma
2011

MYCN and MeCP2 Interaction in Neuroblastoma

publication 10 minutes Evidence: moderate

Author Information

Author(s): Derek M. Murphy, Patrick G. Buckley, Sudipto Das, Karen M. Watters, Kenneth Bryan, Raymond L. Stallings

Primary Institution: Royal College of Surgeons in Ireland

Hypothesis

The association between MYCN binding and regions of DNA hypermethylation may be due to the action of the methyl binding protein MeCP2.

Conclusion

MYCN and MeCP2 interact and co-localize at genomic sites, influencing transcriptional activity in neuroblastoma.

Supporting Evidence

  • MYCN and MeCP2 co-localize to gene promoter regions in neuroblastoma.
  • Co-immunoprecipitation confirmed the interaction between MYCN and MeCP2.
  • Genes bound by both MYCN and MeCP2 showed intermediate expression levels.

Takeaway

This study found that two proteins, MYCN and MeCP2, work together in neuroblastoma cells, which might help us understand how this cancer develops.

Methodology

The study used chromatin immunoprecipitation and microarray analysis to examine the binding of MYCN and MeCP2 to genomic sites.

Limitations

The study does not establish a direct causal relationship between MYCN/MeCP2 interaction and neuroblastoma pathogenesis.

Participant Demographics

The study focused on the Kelly neuroblastoma cell line, derived from a female patient.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1371/journal.pone.0021436

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication